STOCK TITAN

Mediwound - MDWD STOCK NEWS

Welcome to our dedicated page for Mediwound news (Ticker: MDWD), a resource for investors and traders seeking the latest updates and insights on Mediwound stock.

MediWound Ltd (Nasdaq: MDWD) is a biopharmaceutical innovator developing enzymatic therapeutics for non-surgical wound care. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic developments.

Access consolidated information about NexoBrid adoption, EscharEx clinical trials, and pipeline progress. Stay informed about financial results, partnership announcements, and market expansion initiatives directly impacting MediWound's position in wound care innovation.

Key updates include FDA/EMA regulatory decisions, burn treatment protocols, chronic wound therapy breakthroughs, and peer-reviewed research findings. All content is verified through primary sources to ensure accuracy for investment and clinical decision-making.

Bookmark this page for streamlined access to MediWound's latest developments. Combine our updates with SEC filings and earnings call transcripts for comprehensive analysis of this enzymatic therapeutics leader.

Rhea-AI Summary
MediWound Ltd. to participate in H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.2%
Tags
conferences
-
Rhea-AI Summary
MediWound Ltd. (Nasdaq: MDWD) announced progress on EscharEx Phase III study protocol, two key research collaborations, and financial results. The company also provided a corporate update, including a cash balance of $51.3 million and a conference call on August 16, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
-
Rhea-AI Summary
MediWound Ltd. has announced a research collaboration agreement with Mölnlycke for its upcoming Phase III study of EscharEx® in venous leg ulcers (VLUs). Mölnlycke will provide its Mepilex® Up dressing along with other dressings for the study. The study aims to evaluate the efficacy and safety of EscharEx in the debridement of chronic wounds, with a focus on VLUs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
Rhea-AI Summary
MediWound Ltd. has entered into a research collaboration agreement with MIMEDX Group, Inc. for a Phase III study in venous leg ulcers (VLUs). MIMEDX will provide its placental tissue allograft EPIFIX® for the wound healing phase of the study. The goal is to maintain consistency and optimize healing potential. EscharEx, the product being evaluated, aims to debride chronic wounds in VLUs. This study is expected to provide valuable insights to the wound care industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.13%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.53%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.46%
Tags
Mediwound

Nasdaq:MDWD

MDWD Rankings

MDWD Stock Data

184.81M
7.99M
19.75%
47.68%
8.65%
Biotechnology
Healthcare
Link
Israel
Yavne